Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:HIMS 29 September 2025 - 12 March 2026

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket trading Thursday, after closing up 10.3% Wednesday. The rally follows a deal with Novo Nordisk that ends a patent dispute and will return FDA-approved Wegovy and Ozempic to Hims’ platform later this month. Analysts raised targets but warned branded drugs may bring lower margins. Hims also disclosed an SEC probe and a Justice Department referral.
12 March 2026
···
Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares jumped 5.9% to $23.47 Tuesday after announcing a distribution deal with Novo Nordisk, extending a two-day gain to 49%. Novo withdrew its lawsuit against Hims as part of the pact, which will bring Ozempic and Wegovy to Hims’ platform and phase out most compounded GLP-1 drugs. Analysts raised price targets but warned branded drugs could lower margins. Regulatory risks remain.
11 March 2026
··
Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Health shares jumped premarket Monday after reports that Novo Nordisk will sell weight-loss drugs through its platform, with an announcement expected the same day. The move follows a recent patent dispute and comes as the FDA increases scrutiny of compounded GLP-1 drugs. Hims previously pulled a compounded Wegovy pill after FDA threats and a Novo lawsuit. The companies had partnered before but split last June over marketing concerns.
9 March 2026
···
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares rose 0.3% premarket after a 2.3% gain Wednesday, closing at $15.82. The company disclosed in its annual report that it faces an SEC investigation, a Justice Department referral, and a patent lawsuit from Novo Nordisk over compounded semaglutide products. BTIG downgraded the stock, citing regulatory risks and weak guidance. Citi cut its price target to $13.25 and maintained a “sell” rating.
26 February 2026
···
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers Health shares dropped 4.2% to $18.52 premarket Tuesday after plunging 16% Monday. The company halted its compounded semaglutide pill following warnings from U.S. regulators and a new patent lawsuit by Novo Nordisk. The FDA signaled plans to restrict non-approved GLP-1 drugs and may take legal action. The Department of Health and Human Services referred Hims to the Justice Department.
10 February 2026
···
Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen stock drops nearly 2% as Dow drag builds — what AMGN investors watch next

Amgen shares dropped 1.8% to $377.28 in mid-afternoon trading Monday, weighing on the Dow Jones Industrial Average. The decline followed news of an FDA request to withdraw rare-disease drug Tavneos and a sharp 48% fall in Enbrel sales last quarter. Broader drug stocks lagged while traders awaited key U.S. jobs and inflation data later in the week.
9 February 2026
····
Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk shares jumped 8.3% in Copenhagen after Hims & Hers scrapped plans to sell a $49 compounded semaglutide weight-loss pill. The move follows U.S. regulatory warnings and legal threats over mass-marketed compounded GLP-1 drugs. The FDA signaled enforcement action against unapproved compounded versions. Eli Lilly plans to launch a competing weight-loss pill in April.
9 February 2026
····
Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Hims & Hers will stop offering a compounded semaglutide pill after the FDA signaled a crackdown on copycat GLP-1 drugs. Hims shares fell 15.9% to $19.36 on Friday. Molina Healthcare plunged over 28% after forecasting 2026 profit far below expectations and announcing an exit from Medicare Advantage prescription drug plans. The Health Care Select Sector SPDR Fund closed up 1.85% at $157.71.
8 February 2026
··
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
····
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
···
Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next

Hims & Hers Health (HIMS) stock slides premarket after Amazon’s Wegovy pill move — what traders watch next

Hims & Hers shares fell 2.2% to $31.00 in premarket trading Monday after a 6.4% drop Friday. The decline followed Amazon Pharmacy’s move to offer Novo Nordisk’s Wegovy weight-loss pill nationwide, intensifying competition in the online obesity drug market. Investors are watching Hims’ upcoming earnings for signs of pressure on its GLP-1 business and marketing costs.
12 January 2026
·
Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers Health shares dropped 6.4% to $31.69 Friday, extending a two-day slide to 11% after Amazon Pharmacy entered the Wegovy weight-loss pill market. BofA cut its price target and kept an Underperform rating, citing high 2026 estimates. The stock closed below key moving averages and neared oversold levels. The FDA previously warned the company over marketing claims for compounded weight-loss drugs.
10 January 2026
··
Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers stock slides as Amazon starts selling Novo Nordisk’s new Wegovy pill

Hims & Hers shares dropped 5.3% to $32.06 after Amazon Pharmacy began offering Novo Nordisk’s Wegovy weight-loss pill. Bank of America cut its price target on Hims, citing margin and spending risks for 2026. The stock fell from an intraday high of $34.35. Investors are watching for signs of pricing pressure and updated forecasts ahead of Hims’ next earnings report.
9 January 2026
··
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

HIMS shares are up about 110% year-to-date, trading near $58 in late September 2025 after peaking at $73 in February and weathering sharp drops on weak Q2 results and FDA warnings. Q2 revenue rose 73% to $544.8 million, missing estimates, with net income at $42.5 million. HIMS expanded into GLP-1 weight-loss drugs and new prescription categories, and agreed to acquire UK-based Zava for European growth.
29 September 2025
·

Stock Market Today

  • LinQ Minerals Insider Buys AU$100k Shares, Boosting Stake by 121%
    April 9, 2026, 5:09 PM EDT. LinQ Minerals (ASX:LNQ) Independent Non-Executive Director John Holliday purchased AU$100,000 worth of shares at AU$0.55 each, raising his holdings by 121%. This recent insider purchase is the largest by an individual in the last year and occurred above the current price of AU$0.40, indicating possible confidence in the firm's prospects. Insiders collectively hold 22% of LinQ Minerals, valued at approximately AU$18 million, showing moderate alignment with shareholders. However, the company reported a loss in the past year and carries six warning signs in investment analysis, posing risks. Despite this, insider buying suggests optimism about LinQ Minerals' future outlook.

Latest article

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
Oil Prices Today: Brent, WTI Rebound as Fragile Iran Ceasefire Leaves Hormuz Choked

Oil Prices Today: Brent, WTI Rebound as Fragile Iran Ceasefire Leaves Hormuz Choked

9 April 2026
Oil prices rebounded Thursday as traffic through the Strait of Hormuz stayed below 10% of normal, with just seven ships passing in 24 hours. Brent crude rose 1% to $95.65 a barrel, while U.S. WTI climbed 3.2% to $97.39. North Sea Forties crude hit a record $146.43. Major shippers and banks warned supply disruptions could persist for weeks despite the U.S.-Iran ceasefire.
Natural Gas Price Today: Europe’s TTF Holds Near €44 as EU Says Supply Is Safe for Now

Natural Gas Price Today: Europe’s TTF Holds Near €44 as EU Says Supply Is Safe for Now

9 April 2026
European natural gas prices hovered near 44 euros per megawatt hour Thursday after a 15% drop in the Dutch TTF benchmark. Brussels reported no immediate supply risk from the Iran crisis, but ship traffic through the Strait of Hormuz remained below 10% of normal. QatarEnergy restarted some LNG production, though full recovery depends on shipping. Goldman Sachs cut its TTF price forecast, citing possible volatility if disruptions persist.
Go toTop